Clinical Trial Update: Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating efficacy and safety of anti-CD25 rhMAb for steroid-refractory chronic graft-versus-host disease (cGVHD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Anti-CD25 rhMAb (anti-CD25 recombinant human monoclonal antibody)

Snippet

Sponsor: Peking University People's Hospital | Conditions: cGVHD | Phase 4 | Status: NOT_YET_RECRUITING